Immuron Limited.
IMRN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Immuron Limited is a biopharmaceutical company focused on developing and commercializing orally delivered polyclonal antibodies for the treatment of gut-mediated diseases. Their primary focus is on developing products to address unmet medical needs in the areas of infectious diseases, including trav...Show More
Better Health for All
10
Immuron's core business is entirely devoted to health improvement, with its product portfolio delivering exceptional health benefits. Travelan® has demonstrated 84% to >90% protective efficacy in preventing traveler's diarrhea.
1
IMM-529 has shown 80% efficacy in preventing primary Clostridioides difficile infection (CDI), 67% protection against recurrence, and 78.6% efficacy in treating primary CDI in pre-clinical models.
2
All of the company's products, including Travelan®, IMM-529, ProIBS®, and Protectyn®, are designed to improve health outcomes, indicating no revenue from products with negative health impacts. The company emphasizes preventative health, with Travelan® specifically designed to prevent traveler's diarrhea and IMM-529 for the prevention of recurrent CDI.
3
Immuron conducts randomized, double-blind, placebo-controlled clinical trials for its products, such as Travelan®,
4
and has received FDA Investigational New Drug (IND) application clearance for Travelan®
5
and for a Campylobacter Challenge Trial,
6
indicating adherence to ethical trial standards. The company's products address conditions affecting vulnerable populations like the elderly and immunosuppressed patients,
7
but there is no evidence of specific programs to ensure equitable access for these groups. Immuron funds research activities through its existing budget,
8
but no specific percentage of R&D or capital allocation for health improvement is provided. The company addresses antimicrobial resistance, a global health threat,
9
but no specific actions taken during public health emergencies are detailed. Immuron uses patented technology,
10
but there is no information on its approach to patent flexibility in relation to global health needs.
Fair Money & Economic Opportunity
0
Immuron Limited is a biopharmaceutical company focused on developing and commercializing orally delivered polyclonal antibodies.
1
The provided articles, including corporate governance statements, investor presentations, and financial reports, do not contain any information related to financial services, lending, insurance, or banking activities.
2
As such, all KPIs under the 'Fair Money & Economic Opportunity' value are not applicable to the company's core business operations, as it does not offer financial products or services to consumers.
3
Fair Pay & Worker Respect
0
No evidence available to assess Immuron Limited on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Immuron Limited on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Immuron Limited on Honest & Fair Business.
Kind to Animals
-40
Immuron Limited partners with dairy companies that uphold 'highest standards' including Animal Health and Welfare guidelines.
1
These partners collect a small portion of colostrum, ensuring ample supply for calves.
2
The company engages in animal testing for medical analysis and clinical research purposes, specifically noting that antibodies in IMM-529 were generated against C. difficile virulence components in both human and animal subjects.
3
Immuron also mentions access to 'gold standard' animal testing models at CSIRO Animal Health Laboratories.
4
No War, No Weapons
0
Immuron Limited is a biopharmaceutical company focused on developing treatments for gut-mediated diseases. The company has received funding from the US Department of Defense (DoD) for R&D related to diseases affecting military personnel, specifically for Travelan, a treatment for traveler's diarrhea.
1
This funding, totaling $6.2 million (Article 5) and $2.3 million (Article 6), is for medical research and development of a civilian product, not for arms manufacturing, military equipment, or direct combat support.
2
Therefore, the company has no revenue from arms or defense contracts, nor does it develop dual-use technologies with military applications. There is no evidence of involvement in controversial weapons, or any defense-related business activities that would require board oversight, humanitarian procurement standards, or ethical red lines related to weapons.
Planet-Friendly Business
0
No evidence available to assess Immuron Limited on Planet-Friendly Business.
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to Immuron Limited's respect for cultures and communities. The articles either explicitly state 'Not mentioned' or 'Not applicable' for these metrics, or they are irrelevant to the company's performance in this area, focusing instead on financial, corporate governance, or general industry topics.
1
Safe & Smart Tech
-20
Immuron Limited's policy states data retention for a minimum of 7 years, which aligns with retention periods of 7+ years.
1
The company complies with Australian Privacy Principles (APPs), the Privacy Act 1988 (Cth), related Australian legislation, and GDPR for EU users, indicating a standard approach to regulatory compliance.
2
Users can access and correct their personal information, which represents industry-standard user privacy controls.
3
Zero Waste & Sustainable Products
0
No information relevant to Immuron Limited's zero waste and sustainable products performance, or any of the specific KPIs, was found in the provided article.
1